Sirion’s Durezol Gets Priority Review, Late June Action Date
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Butler tells “The Pink Sheet” DAILY Durezol would improve on the current standard of care by offering twice-daily dosing for post-operative ocular inflammation.
You may also be interested in...
Sirion’s Durezol Cleared For Post-Op Ocular Use
The first-in-class topical steroid is set to launch in the fourth quarter.
Sirion’s Durezol Cleared For Post-Op Ocular Use
The first-in-class topical steroid is set to launch in the fourth quarter.
FDA Panel Supports Sirion’s Durezol, But Dosing May Not Provide Market Niche
Twice-daily dosing would provide a convenience advantage for Durezol over other corticosteroids.